Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.73 |
| ▸ | EGFR | P00533 | 7/20 | 0.73 |
| ▸ | INSR | P06213 | 9/20 | 0.63 |
| ▸ | EML4 | Q9HC35 | 5/20 | 0.63 |
| ▸ | IGF1R | P08069 | 5/20 | 0.63 |
| ▸ | ROS1 | P08922 | 3/20 | 0.63 |
| ▸ | FER | P16591 | 3/20 | 0.63 |
| ▸ | LTK | P29376 | 3/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.63 |
| ▸ | BTK | Q06187 | 3/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.63 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
| ▸ | GAK | O14976 | 2/20 | 0.63 |
| ▸ | ERN1 | O75460 | 2/20 | 0.63 |
| ▸ | STK10 | O94804 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027412 | 0.93 | ALK (0.85) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL19027868 | 0.91 | ALK (0.63) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL19027408 | 0.89 | ALK (0.58) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL22520226 | 0.88 | EGFR (0.58) | ALKEGFRINSRIGF1RKCNH2 | |
| SCHEMBL21364015 | 0.87 | ALK (0.65) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL19027555 | 0.87 | ALK (0.71) | ALKEGFRINSREML4ROS1 | |
| SCHEMBL19027794 | 0.87 | ALK (0.95) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL22497639 | 0.86 | ALK (0.71) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL19027796 | 0.86 | ALK (0.81) | ALKEGFRINSREML4IGF1R | |
| SCHEMBL21363944 | 0.85 | EGFR (0.78) | ALKEGFRINSREML4IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2018-12-27 | — | — | US | disclosed |
| EP-3392245-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017101803-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | 合肥中科普瑞昇生物医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | ALK, EGFR, NPM1 | ALK 1/4885EGFR 2/4885INSR 909/4885 |
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | ALK 1/4885EGFR 2/4885INSR 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.